Modifying mesenchymal stem cells (MSCs) — a type of stem cell found in various tissues and, in this case, taken from the umbilical cord of mice — and using clumps of them in a mouse model of systemic sclerosis (SSc) was found to ease signs of skin and lung…
Efzofitimod was found to be generally safe and well tolerated by patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a proof-of-concept Phase 2 study. No treatment-related serious side effects were reported, with efzofitimod showing early signs of efficacy. In addition, the last patient visit has been completed in…
The immune signaling protein interleukin-40, or IL-40, may be involved in developing systemic sclerosis (SSc), a study from the Czech Republic suggests. Elevated levels of IL-40 were found in the bloodstream of adults with SSc and correlated with worse disease activity, digestive problems, and markers of inflammation and fibrosis.
The first patient with systemic sclerosis (SSc) has been dosed in a Phase 1 trial of Adicet Bio’s investigational CAR T-cell therapy for autoimmune conditions, called ADI-001, the company has announced. Recruitment in the open-label trial (NCT06375993) is ongoing at one site in California. It’s expected…
The National Scleroderma Foundation has recognized several individuals — leaders in advocacy, fundraising, and patient support — and regional chapters for their service in advancing scleroderma awareness and research. The 12 awards, given at the 2025 National Scleroderma Conference, held July 18-20 in St. Louis, were given for…
The Scleroderma Research Foundation (SRF) announced that it has joined Vie Ventures to advance research and accelerate the development of innovative therapies for scleroderma and other autoimmune diseases. The venture capital firm unites biotech investors with autoimmune disease organizations to fund the translation of scientific discoveries into…
Scientists in China have identified four distinct subtypes of systemic sclerosis-associated interstitial lung disease (SSc-ILD), each characterized by different clinical characteristics, a new study found. With these four subtypes identified, the team then analyzed outcomes for each subtype and found differing survival rates and factors associated with mortality, which…
Galderma is launching a Phase 2 clinical trial to test nemolizumab, an antibody the company is developing to ease inflammation and scarring, known medically as fibrosis, in systemic sclerosis (SSc). Recruitment is planned to begin in North America, South America, and Europe in the second half of this…
Levels of certain types of immune cells are abnormally high in some people with systemic sclerosis (SSc), and this may be linked to serious kidney and lung complications — such as renal crisis and interstitial lung disease (ILD) — according to a study of blood cells from patients.
Two patients with systemic sclerosis (SSc) had reduced skin thickness after treatment with the investigational CAR T-cell therapy rese-cel (resecabtagene autoleucel) and discontinuation of immunomodulators and steroids. These initial results came from the Phase 1/2 RESET-SSc clinical trial (NCT06328777), one of several trials that rese-cel developer…
Get regular updates to your inbox.